Compare Keysight Technologies Inc (KEYS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Merck & Co., Inc. — how do they compare? Keysight Technologies Inc trades at $326.05 (market cap $53.68B), while Merck & Co., Inc. trades at $125.62 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 5.7× Keysight Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | MRK | |
|---|---|---|
Market Cap | $53.68B | $307.25B |
Sector | Technology | Health |
52-Week High | $373.34 | $129.52 |
52-Week Low | $158.51 | $77.60 |
Enterprise Value | $54.03B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $313.97, down 0.61% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong profitability with a 17.31% net margin and has secured strategic partnerships, including a European Space Agency contract for 5G network development announced July 15, 2026. Analyst consensus remains strongly bullish with an $396.56 price target, though valuation multiples appear elevated with a P/E of 50.87.
KEYS presents a growth opportunity driven by AI and 5G testing demand, but faces risks from high valuation and volatile cash flows. The stock's near-term direction hinges on Q2 2026 earnings versus the $2.46 EPS estimate, with support at $309 critical for maintaining bullish technical structure.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
